BioPhotas has announced a series of promotions and positional changes within the company at the start of 2024. The new positions are spread across a variety of departments including sales, manufacturing, marketing and management.
Jerry Gutierrez has been promoted to director of international and government sales. Gutierrez has been with BioPhotas for eight years working in various roles for the company, most recently as a regional manager for the clinical sales specialist team.
With Jerry’s appointment, Sean McPhillips has been promoted to fill the vacant regional manager role. BioPhotas has also promoted Kathryn Feather to senior manager of professional marketing. Feather has been with the company since January 2020.
Changes within manufacturing operations include the promotion of Jose Marquez to director of operations, where he will manage the growing demands of production and purchasing. Jose joined the company in August of 2022 and has more than 20 years of manufacturing and operations management experience with companies such as Manhattan Beachwear
Curtis A. Cluff has been named CEO of BioPhotas. Cluff joined the company in October 2022 as the president and chief financial officer and brings 25 years of experience in building successful biotech and aesthetic medicine companies, creating industry-leading brands and accelerating global growth.
Curtis has previously served in C-level operational, finance and executive roles, including six years as CFO, interim president and EVP of operations for Obagi Medical Products and then later seven years as CEO of Envy Medical. In this expanded role, Curtis will work closely with founding CEO, Patrick Johnson, who will continue as the executive chairman of the board of directors, while also serving as the chief innovation officer.
"I have been working closely with Curtis for more than a year and I am confident he is the right person to maintain the company’s accelerated growth trajectory as the CEO," said Patrick. “The coming year will be an exciting time and I look forward to continuing the collaborative partnership that Curtis and I have developed while placing greater focus on the product innovations and new indications for use. These changes represent the founder’s succession goals to form a strong management team for this next evolution of the company’s growth."
Curtis said, "It has been a privilege to work with Patrick and I am honored to take on the CEO mantle with the support of such an amazingly talented leader. Celluma is and will continue to be the light therapy of choice for professionals and consumers who value FDA-cleared and science-backed treatments for fine-lines and wrinkles, acne, and hair restoration, as well as muscle/joint pain.”
Along with the promotion of Cluff, Denise Ryan has been promoted to chief clinical affairs officer. During her 12-year history with the company, Denise has served in multiple roles, most recently as vice president of brand management. Her new responsibilities will include the oversight of clinical research, professional and clinical network development and the further development of BioPhotas’ thought leadership programs.
Wayne (Tony) May has been promoted to chief financial officer and treasurer. May's responsibilities will include all finance, accounting and information technology activities. Having joined BioPhotas in December 2022, May has been serving as the company's corporate controller. Prior to joining BioPhotas, May held positions at Southern California Technical Arts and AllFast Systems.
"This is an exciting time in the company’s development, and we have an exceptional team in place,” said Patrick. "These promotions reflect the talent and accomplishments of these individuals and will facilitate greater management focus on the company's strategic growth, technology development and partnering initiatives."
"We have built something special with Celluma Light Therapy,” said Cluff. “These are just a few of the outstanding individuals who are making it happen every day, and I am delighted to announce these promotions as a reflection of both their individual accomplishments and the well-earned respect that have garnered among their colleagues. The recent additions to our leadership team along with these key management appointments point to the trajectory the company is on as we continue the legacy of highly effective products that are backed by science."